002675 东诚药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.1434.4313.9724.4046.720
总资产报酬率 ROA (%)1.0172.1912.1992.5803.882
投入资产回报率 ROIC (%)1.3162.8242.7443.1704.764

边际利润分析
销售毛利率 (%)53.05950.96647.14044.86742.942
营业利润率 (%)9.5227.7577.69610.43012.511
息税前利润/营业总收入 (%)15.94813.07710.32911.25212.608
净利润/营业总收入 (%)6.3415.6344.9307.7619.847

收益指标分析
经营活动净收益/利润总额(%)102.736103.752100.357133.174123.056
价值变动净收益/利润总额(%)3.684-7.508-5.895-8.340-8.800
营业外收支净额/利润总额(%)0.005-0.566-0.777-1.299-0.600

偿债能力分析
流动比率 (X)1.4481.6411.4641.2691.334
速动比率 (X)1.1911.3161.0950.8060.884
资产负债率 (%)42.07140.76537.79233.24235.400
带息债务/全部投入资本 (%)18.94612.26316.55420.06324.577
股东权益/带息债务 (%)322.234503.857397.083361.642290.453
股东权益/负债合计 (%)113.569115.691137.302177.740164.050
利息保障倍数 (X)2.4822.4383.83711.77873.434

营运能力分析
应收账款周转天数 (天)141.349123.217105.54989.56286.318
存货周转天数 (天)144.561157.867183.983197.538178.786